ANIP
ANI Pharmaceuticals, Inc.
Set alert
- YTD
- -8.79%
- 1 year
- -21.68%
- Open
- 73.27
- Prev close
- 73.16
- Mkt cap
- 1.65B
- Vol
- 286.90K
- Avg vol
- 386.56K
- EPS
- 4.62
- P/E
- 15.58
- Div yield
- 0.00%
More statistics
- Low
- 71.90
- High
- 73.54
- Forward P/E
- 7.14
- Beta
- 0.49
- Short ratio
- 8.21
- Inst. own
- 107.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 73.06
- 200-d avg
- 77.72
- 1y target
- 105.78
News
1 week ago globenewswire.com
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results…
-
1 week ago benzinga.com
ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the…
1 week ago globenewswire.com
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg.…
1 week ago defenseworld.net
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in Stock
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at…
2 weeks ago zacks.com
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 weeks ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
3 weeks ago defenseworld.net
Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)
Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
1 month ago globenewswire.com
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
1 month ago zacks.com
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
1 month ago seekingalpha.com
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is…
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85
Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.
-
1 month ago benzinga.com
ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension
Approval for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®."The…
1 month ago globenewswire.com
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug…
1 month ago seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago defenseworld.net
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
1 month ago globenewswire.com
ANI Pharmaceuticals to Present at September Investor Conferences
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along…
2 months ago globenewswire.com
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the…
2 months ago defenseworld.net
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of…
2 months ago zacks.com
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
2 months ago zacks.com
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
2 months ago zacks.com
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
2 months ago benzinga.com
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90
Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.
2 months ago seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to…
-
2 months ago benzinga.com
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est
ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080…
-
2 months ago benzinga.com
ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 by 7.8 percent. This is a 22.78 percent increase over earnings of…
3 months ago benzinga.com
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
-
3 months ago benzinga.com
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91
Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.
-
3 months ago benzinga.com
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter…
-
3 months ago benzinga.com
ANI Pharmaceuticals Reveals Trial Court Denied Company’s Motion For A New Trial And Judgment As A Matter Of Law For Unjust Enrichment; Co. Intends To Appeal Rulings To The Delaware Supreme Court And Continue To Seek To Recover The Value Of The Assets It Sold To CG Oncology In 2010
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover…
-
3 months ago benzinga.com
ANI Pharmaceuticals Announces Topline Data From Its Phase 4 SYNCHRONICITY Clinical Trial Of The Fluocinolone Acetonide Intravitreal Implant; Trial Met Both Co-Primary Endpoints
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide…
-
3 months ago benzinga.com
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.
-
5 months ago benzinga.com
ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est.
ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 analyst estimate. Raises FY2026 sales outlook from $1.055 billion-$1.115 billion to $1.080…
-
5 months ago benzinga.com
ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.30 by 56.49 percent. This is a 20.59 percent increase over earnings of…
-
6 months ago benzinga.com
ANI Pharmaceuticals Announces Launch Of Pimozide Tablets 1 Mg And 2 Mg, Generic Version Of Reference Listed Drug Orap, With 180-Day CGT Exclusivity
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug…
-
6 months ago benzinga.com
ANI Pharma Launches Isosorbide Mononitrate Tablet USP, Generic Version Of Reference Listed Drug Monoket
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application…
-
6 months ago benzinga.com
ANI Pharma Announces Publication Of Results From NEW DAY Clinical Trial Involving ILUVIEN For Use In Patients With Diabetic Macular Edema In Ophthalmology, The Journal Of The American Academy Of Ophthalmology
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal…
8 months ago benzinga.com
Earnings Scheduled For February 27, 2026
Earnings Scheduled For February 27, 2026
11 months ago benzinga.com
Earnings Scheduled For November 7, 2025
Earnings Scheduled For November 7, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Delaware Court Gives Unanimous Verdict Detailing That CG Oncology Will Owe No Future Royalties Or Other Payments To ANI Pharmaceuticals
CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder…
-
1 year ago benzinga.com
Earnings Scheduled For February 28, 2025
Earnings Scheduled For February 28, 2025
1 year ago benzinga.com
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
1 year ago benzinga.com
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
-
2 years ago benzinga.com
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.